Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cidara Thera (NQ: CDTX )

2.310 USD -0.030 (-1.28%)
Official Closing Price Updated: 6:30 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cidara Thera

< Previous 1 2 3 4 5 Next >
Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
From GlobeNewswire News Releases
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
UTILITY Therapeutics Joins Antimicrobials Working Group
The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur... 
From PR Newswire
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium
New analyses from completed Phase 2 STRIVE trial support once-weekly, long-acting rezafungin for the treatment of candidemia and invasive candidiasis in high-risk patient populations 
From GlobeNewswire News Releases
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium
From GlobeNewswire News Releases
Cidara Therapeutics Announces Key Additions to its Board of Directors
From GlobeNewswire News Releases
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations
Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara’s antifungal and antiviral programs 
From GlobeNewswire News Releases
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
From GlobeNewswire News Releases
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020
From GlobeNewswire News Releases
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Fourth Consecutive Year
Employee feedback places Cidara among top 20 small companies in the area 
From GlobeNewswire News Releases
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
From GlobeNewswire News Releases
Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
From GlobeNewswire News Releases
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
From GlobeNewswire News Releases
Cidara Therapeutics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
From GlobeNewswire News Releases
Cidara Therapeutics Announces Formation of Scientific Advisory Board
Comprised of World-Renowned Experts in Virology, Fungal Diseases and Hematology 
From GlobeNewswire News Releases
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
From GlobeNewswire News Releases
Cidara Therapeutics Added to Russell 3000® Index
From GlobeNewswire News Releases
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
From GlobeNewswire News Releases
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
From GlobeNewswire News Releases
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
From GlobeNewswire News Releases
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
From GlobeNewswire News Releases
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
From GlobeNewswire News Releases
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.